Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

The efficacy of standard antidepressants is limited for many patients with mood disorders such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent need to develop novel therapeutics. Both clinical and preclinical studies have implicated glutamatergic system dysfunction...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	CNS drugs Jg. 35; H. 5; S. 527 - 543
Hauptverfasser:	Henter, Ioline D., Park, Lawrence T., Zarate, Carlos A.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Cham Springer International Publishing 01.05.2021 Springer Nature B.V
Schlagworte:	Alzheimer's disease Animals Antidepressants Antidepressive Agents - pharmacology Antidepressive Agents - therapeutic use Bipolar disorder Bipolar Disorder - drug therapy Bipolar Disorder - physiopathology Brain-derived neurotrophic factor Cycloserine Depressive Disorder, Major - drug therapy Depressive Disorder, Major - physiopathology Developmental stages Dextromethorphan Emotional disorders Excitatory Amino Acid Agents - pharmacology Excitatory Amino Acid Agents - therapeutic use Glutamatergic transmission Glutamic Acid - metabolism Glutamic acid receptors Glutamic acid receptors (ionotropic) Glutamic acid receptors (metabotropic) Glycine Humans Ketamine Kinases Medicine Medicine & Public Health Mental depression Mental disorders Mood Mood disorders Mood Disorders - drug therapy Mood Disorders - physiopathology N-Methyl-D-aspartic acid receptors Neurology Neurosciences Nitrous oxide Pathophysiology Pharmacotherapy Psychiatry Psychopharmacology Quinidine Rapamycin Receptors, Glutamate - drug effects Receptors, Glutamate - metabolism Review Article Sarcosine TOR protein United States > US
ISSN:	1172-7047, 1179-1934, 1179-1934
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!